Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Biochemical Pharmacology|June 5, 2020
Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzymeDimitrios Vagiannis, Zhang Yu, Eva Novotna, et al.
Expert Review of Respiratory Medicine|September 1, 2023
Mechanisms underlying corticosteroid resistance in patients with asthma: a review of current knowledgeJavier Milara, Anselm Morell, Inés Roger, et al.
Chemico-Biological Interactions|February 1, 2019
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3Neslihan Bukum, Eva Novotna, Anselm Morell, et al.
Archives of Toxicology|October 7, 2020
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergismAnselm Morell, Eva Novotná, Jaroslav Milan, et al.
Archives of Toxicology|June 27, 2020
Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?Eva Novotná, Anselm Morell, Neslihan Büküm, et al.
The Journal of Allergy and Clinical Immunology|September 19, 2016
MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polypsJavier Milara, Anselm Morell, Beatriz Ballester, et al.
International Journal of Molecular Sciences|July 29, 2023
Obacunone Photoprotective Effects against Solar-Simulated Radiation-Induced Molecular Modifications in Primary Keratinocytes and Full-Thickness Human SkinPaula Montero, Maria José Villarroel, Inés Roger, et al.
Allergy|July 7, 2018
Mucin 1 deficiency mediates corticosteroid insensitivity in asthmaJavier Milara, Anselm Morell, Alfredo de Diego, et al.
The Journal of Allergy and Clinical Immunology|August 28, 2014
Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polypsJavier Milara, Teresa Peiró, Miquel Armengot, et al.
Biochemical Pharmacology|March 4, 2019
Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transportersAles Sorf, Eva Novotna, Jakub Hofman, et al.
Pageof 2